Last updated: February 16, 2026
What is NDC 00115-1695?
NDC 00115-1695 is marketed as Xyrem (sodium oxybate), manufactured by Jazz Pharmaceuticals. It is primarily used to treat narcolepsy with cataplexy and has orphan drug status in the U.S.
What is the current market landscape for Xyrem?
Market Size and Revenue
- Globally, the narcolepsy therapeutics market was valued at approximately $1.2 billion in 2022.
- Xyrem accounts for over 60% of the U.S. narcolepsy market, generating roughly $900 million in annual revenues (as of 2022).
Market Share
| Product |
Estimated Market Share (2022) |
Notes |
| Xyrem |
60% |
Dominates narcolepsy treatment |
| Off-label options |
25% |
Modafinil, armodafinil, other options |
| New entrants |
15% |
Emerging therapies, biosimilars |
Key Competitors
- Wakix (pitolisant) by Harmony Biosciences
- Sunosi (solriamfetol) by Jazz Pharmaceuticals
- Off-label stimulants: Modafinil, Armodafinil
Regulatory Dynamics
- The FDA approved Wakix in August 2019 for narcolepsy.
- The approval of generic sodium oxybate formulations is unlikely soon; patent exclusivity generally extends until 2030, with possible extensions.
What are the price trends and projections?
Current Pricing
- Average wholesale price (AWP): $52 per gram
- Typical prescribed dose: 9 grams/night (split dose)
- Annual drug cost per patient: ~$170,000 (assuming no discounts or insurance coverage variances)
Pricing Components
- High manufacturing costs due to complex synthesis and stringent storage requirements.
- Extensive regulatory oversight limits generic competition.
Projected Price Trends
| Year |
Estimated Average Price per Gram |
Rationale |
| 2023 |
$52 |
Current price maintained amidst high demand |
| 2024 |
$52 |
Market stability, no major competitive shifts |
| 2025 |
$50–$53 |
Slight price compression expected as biosimilar competition matures |
| 2030 |
$48–$50 |
Potential entry of biosimilars or generic versions, pending patent expiry |
Note: Biosimilar or generic sodium oxybate market entry remains unlikely before 2030 due to patent protections.
How will market dynamics influence future prices?
- Patent Durations: Patents are scheduled to expire around 2030; extensions unlikely due to regulatory policies.
- Biosimilar Entry: Entry unlikely before 2028-2030; when it occurs, price erosion could reach 30-40%.
- Market Penetration: Adoption of alternative therapies like Wakix and Sunosi could limit upside potential but won't significantly impact sodium oxybate's dominant position in severe cases.
- Insurance and Reimbursement Policies: Potential for negotiated discounts and rebates affecting net pricing but not wholesale prices.
What are the key factors influencing market growth?
- Increased diagnosis rates: Growing awareness and diagnosis of narcolepsy expand the patient base.
- Advancement in formulations: Extended-release formulations may improve adherence, increasing long-term usage.
- Shift in treatment paradigms: Introduction of non-sodium oxybate options may reallocate market share but unlikely to eliminate sodium oxybate's role in severe cases.
How do regulatory and policy trends impact future valuation?
- Federal efforts to curb opioid-like scheduling may influence sodium oxybate's DEA scheduling, potentially affecting manufacturing and distribution costs.
- The DEA classifies sodium oxybate as Schedule III, limiting pharmacy distribution channels, which keeps prices high.
- Loosening of restrictions or approval of biosimilars would lower prices but remains unlikely before 2030.
Key Takeaways
- NDC 00115-1695 (Xyrem) holds a dominant position in narcolepsy treatment with revenue around $900 million annually.
- Price stability is expected through 2024; slight declines likely thereafter with biosimilar competition not before 2030.
- Market expansion depends on improved diagnosis rates and patient adherence, but competition from newer agents remains limited.
- Patent duration and regulatory protections suggest limited generic competition until at least 2030.
- Pricing pressure from biosimilars could eventually reduce costs by 30-40%.
FAQs
1. When are biosimilar sodium oxybate products expected to enter the market?
Biosimilar sodium oxybate is unlikely to enter before 2028-2030, considering patent protections and regulatory approvals.
2. How will increased competition affect drug prices?
Introduction of biosimilars or generics could lower prices by 30-40%, but regulatory delays and patent protections may postpone price erosion.
3. Are there alternative treatments for narcolepsy that could impact Xyrem's market?
Yes, drugs like Wakix and Sunosi are FDA-approved for narcolepsy and might reduce long-term reliance on sodium oxybate for some patients.
4. What is the current annual revenue for NDC 00115-1695 in the U.S.?
Approximately $900 million, representing over 60% of the narcolepsy treatment market.
5. How do insurance policies influence the actual cost to patients?
Negotiated rebates, formularies, and coverage policies significantly influence out-of-pocket costs, often reducing the net price paid by patients.
References
- IQVIA, "Pharmaceutical Market Estimates," 2022.
- Jazz Pharmaceuticals, "Xyrem Commercial Product Data," 2022.
- U.S. Food and Drug Administration, "Wakix Approval," August 2019.
- FDA, "Patent and Exclusivity Data for Sodium Oxybate," 2022.
- Market Research Future, "Narcolepsy Therapeutics Market Outlook," 2023.
